Form 4: DiaMedica Director Richard Jacinto II Plans Significant Share Purchase Under 10b5-1 Plan

DiaMedica Therapeutics Inc. Director and 10% owner Richard Jacinto II has disclosed a planned acquisition of 400,000 common shares at $3.50 each, scheduled for July 23, 2025, under a Rule 10b5-1 plan.

Summary

• Richard Jacinto II, a Director and 10% owner of DiaMedica Therapeutics Inc. (DMAC), has reported a planned acquisition of shares.
• The transaction, scheduled for July 23, 2025, involves the acquisition of 400,000 Voting Common Shares.
• The shares are planned to be acquired at a price of $3.50 per share.
• This transaction is being made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged purchase.
• Following this planned acquisition, Richard Jacinto II's indirect beneficial ownership is expected to be 4,958,823 shares, held through an NFS/FMTC Roth IRA.

Sentiment

Score: 8

Explanation: The significant planned share purchase by a Director and 10% owner under a Rule 10b5-1 plan indicates strong insider confidence in the company's valuation and future prospects.

Positives

• The establishment of a Rule 10b5-1 plan by a Director and 10% owner, Richard Jacinto II, to acquire 400,000 common shares signals strong long-term confidence in DiaMedica Therapeutics Inc.'s future prospects.
• A planned acquisition of 400,000 shares at $3.50 each represents a significant commitment by an insider.

Negatives

• No direct negatives are apparent from this insider purchase plan filing.

Risks

• No specific risks are detailed within this Form 4 filing, as it primarily reports an insider transaction plan.

Future Outlook

The filing indicates a forward-looking transaction under a Rule 10b5-1 plan, with a planned acquisition date of July 23, 2025. This suggests a pre-determined strategy for increasing insider ownership, signaling long-term confidence.

Industry Context

Insider purchase plans, especially by a director and significant owner, are often viewed positively by the market as they indicate management's belief in the company's intrinsic value and future prospects, potentially signaling undervaluation or upcoming positive developments.

Comparison to Industry Standards

• This Form 4 filing reports an individual insider transaction plan and does not provide data for direct comparison to industry-wide financial performance benchmarks or specific competitor results.

Related Party Transactions

• The planned transaction involves shares to be held indirectly by an NFS/FMTC Roth IRA FBO Richard Jacinto II, where Richard Jacinto II is the beneficiary, constituting a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase plan as a positive signal, potentially increasing investor confidence and demand for the stock.

Next Steps

• No specific future actions, events, or milestones are detailed within this Form 4 filing beyond the planned transaction date.

Key Dates

Recommendation

The planned acquisition of 400,000 shares by a Director and 10% owner, Richard Jacinto II, at $3.50 per share, under a Rule 10b5-1 plan, strongly suggests long-term insider confidence in DiaMedica Therapeutics Inc.'s current valuation and future growth potential, making it a compelling 'buy' signal for investors.

Keywords

DiaMedica Therapeutics, DMAC, Insider Trading, Form 4, Share Purchase Plan, Richard Jacinto II, Director, 10% Owner, Equity Acquisition, Roth IRA, Rule 10b5-1